COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02891603
Recruitment Status : Recruiting
First Posted : September 7, 2016
Last Update Posted : July 7, 2020
CTI BioPharma
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute